Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
about
Helminth therapy (worms) for induction of remission in inflammatory bowel diseaseHelminths for induction of remission in inflammatory bowel diseaseAdverse effects of biologics: a network meta-analysis and Cochrane overviewOral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's diseaseAdverse effects of biologics: a network meta-analysis and Cochrane overviewAttenuation of TNF-driven murine ileitis by intestinal expression of the viral immunomodulator CrmDPharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adultsOptimal Endpoint of Therapy in IBD: An Update on Factors Determining a Successful Drug WithdrawalProfile of ustekinumab and its potential in patients with moderate-to-severe Crohn's disease.Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanCharacterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn's disease: a systematic review and clinician surveysInflammatory bowel disease: perioperative pharmacological considerations.Fetal exposure to maternal inflammation does not affect postnatal development of genetically-driven ileitis and colitisInflammatory bowel disease: Efficient remission maintenance is crucial for cost containment.Efficacy of early treatment with infliximab in pediatric Crohn's disease.Cystic fibrosis and Crohn's disease: successful treatment and long term remission with infliximab.Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease.Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.Change in the treatment strategy for pediatric Crohn's diseaseTumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysisAssessing patients' satisfaction with anti-TNFα treatment in Crohn's disease: qualitative steps of the development of a new questionnaire.Infliximab to treat Crohn's disease: an update.The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drugSelective improvement of tumor necrosis factor capture in a cytokine hemoadsorption device using immobilized anti-tumor necrosis factor.Cyclopropane fatty acid synthase mutants of probiotic human-derived Lactobacillus reuteri are defective in TNF inhibition.Biologics in paediatric Crohn's disease.In Crohn's Disease, Anti-TNF-α Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells.Anti-arthritic property of crude extracts of Piptadeniastrum africanum (Mimosaceae) in complete Freund's adjuvant-induced arthritis in rats.Unraveling the signaling pathways promoting fibrosis in Dupuytren's disease reveals TNF as a therapeutic targetEnteropathic spondyloarthritis: from diagnosis to treatment.TNFR2 activates MLCK-dependent tight junction dysregulation to cause apoptosis-mediated barrier loss and experimental colitis.Advances in the pathogenesis and treatment of IBDPharmacological characterization of PF-00547659, an anti-human MAdCAM monoclonal antibodyImmunomodulatory and anti-inflammatory effects of chondroitin sulphate.Rheumatic manifestations of inflammatory bowel disease.Time of infliximab therapy initiation and dose escalation in Crohn's disease.Modern Treatments and Stem Cell Therapies for Perianal Crohn's Fistulas.Managing immunosuppression in medical patients.Second Korean guidelines for the management of Crohn's disease.Update on anal fistulae: surgical perspectives for the gastroenterologist.
P2860
Q24201067-F9547A30-B74C-42B9-A210-5C99262C869CQ24234013-80FFF1E8-8039-44F3-A219-7B2C935165C6Q24234197-EB6148AF-D3D1-4222-806F-17E55A0893C5Q24234938-260064CA-416D-4F95-9BBB-A910D51C6C3AQ24235218-154039B2-F713-4DF5-B16D-00C6F95B06FFQ24607556-798AAB8A-7FD1-4158-BCBA-158943F37FFFQ26768280-FC696671-8728-4496-9CCB-C6D61665F983Q26801119-75759B4B-6B11-46C8-852E-1F5D496E26C1Q26825174-7ACE434C-B32C-471E-98EC-B0DF786CC15DQ26829392-60FEADF1-03E5-4FE7-8BCF-4A7E0343E267Q26862821-8D1D516D-E8CB-43C5-9A85-503B8594687CQ30502980-3A263876-03BA-4F9F-8144-0D533C78F88DQ33645831-46C02BDE-48C9-4AE2-8595-661F74CAA4C2Q33646458-3B5C3622-E287-4BD8-BD01-E94B4ECC9A6BQ33782089-1BEEE712-AD31-4758-B1D9-642C86DE2679Q33798912-460D7AE2-8F7B-40BD-B28A-FCE9E689BF47Q33819478-F70FB667-AE5B-4219-AF5B-F6CC0C9A45B6Q33973884-935A0A79-DBC6-4DBE-8898-EE941AB0B57DQ34420755-54CE31C4-8F4F-4AA7-B91E-A2A944F39904Q35052356-14562F4E-51E0-4B97-9DF7-E48AD3488187Q35186984-5554D765-1B5B-4935-8AC7-A72CD326A335Q35304737-07710175-891B-4D7E-B84D-0F5D105CDC77Q35336802-26A1FD82-1E4B-49D2-9D9A-84F0C5650F1CQ35565550-E97F0AD6-451B-486C-832B-048ABA767AC6Q35577828-3556EB00-BB91-47A7-B33B-5C7F85F9C208Q35579308-2D98E90C-D3F3-4838-A34B-E90D6363EAB0Q36063507-48A592AF-7942-45F2-9896-702B60BB23ABQ36281697-BFE2C172-1D23-4877-86F2-144E773403E5Q36673270-E025D24B-461E-4BA8-ABD8-E60AC2291DE7Q36830824-269C8931-32DE-45C4-B2ED-27C2ED17A22FQ37042932-E79ACF88-5F95-4C53-8032-D757A68CA28EQ37219854-28B8B3D6-4970-4B9F-BEB4-114DB22D6C24Q37230907-1E6751AF-3D9F-4714-A087-5A3DFB470DDCQ37310621-3C56362C-927E-4FE5-91A6-050335492095Q37445601-F2923672-23FF-4137-92C6-F2892237ECC2Q37454462-E8D7001E-B8FF-473C-BD62-71B85711C530Q37521494-395F186D-19CC-4AF2-9D98-5A8A19179E83Q37544228-7F33CD53-693D-43A9-BE35-AAFBF7FD8DD2Q37662498-F7F33952-AB3E-4251-B977-BF44EBD95580Q37969124-C4A9797F-C028-4B3D-90A6-35972ADFB906
P2860
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@ast
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@en
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@en-gb
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@nl
type
label
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@ast
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@en
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@en-gb
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@nl
prefLabel
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@ast
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@en
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@en-gb
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@nl
P2860
P1476
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease
@en
P2093
Brian W Behm
Stephen J Bickston
P2860
P356
10.1002/14651858.CD006893
P577
2008-01-23T00:00:00Z